Avacta (AVCT) is a pre-clinical stage biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology. The significant technical and commercial benefits of Affimers are being recognised increasingly through corporate and academic interest, ongoing evaluations, and deal flow. AVCT has just concluded an Affimer therapeutics development and commercial agreement with the global pharma company, LG Chem, worth up
10 Dec 2018
Wake-up call for the market
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Wake-up call for the market
Avacta Group PLC (AVCT:LON) | 48.8 0 0.0% | Mkt Cap: 175.0m
- Published:
10 Dec 2018 -
Author:
Martin Hall -
Pages:
8
Avacta (AVCT) is a pre-clinical stage biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology. The significant technical and commercial benefits of Affimers are being recognised increasingly through corporate and academic interest, ongoing evaluations, and deal flow. AVCT has just concluded an Affimer therapeutics development and commercial agreement with the global pharma company, LG Chem, worth up